Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Study of HR-positive HER2-positive MBC Combined Treatment Plan

NCT05167643 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT05167643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05167643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Study of HR-positive HER2-positive MBC Combined Treatment Plan
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
January 23, 2022
Completion date
August 23, 2024
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hr+ her2 negative breast carcinoma